HK Stock Market Move | ANTENGENE-B(06996) rose more than 6% and reached a clinical cooperation agreement with JUNSHI BIO to advance the joint exploration of ATG-037 and JS207.

ANTENGENE-B (06996) rose by over 6%, by the time this article was written, it had risen by 6.4%, reaching 3.66 Hong Kong dollars, with a turnover of 13.26 million Hong Kong dollars. On the news front, Deqi Pharmaceuticals announced this morning that the company had reached a clinical cooperation agreement with JUNSHI BIO. Both parties will jointly explore the synergistic potential of Deqi Pharmaceuticals' ATG-037 (oral CD73 small molecule inhibitor) and JUNSHI BIO's JS207 (anti-PD-1/VEGF bispecific antibody) in the combined treatment of mainland Chinese cancer patients. The company stated that in the background of the clinical challenge of resistance to immune checkpoint inhibitors (CPI), ATG-037 has demonstrated strong reversal of resistance in combination with CPI in Phase I trials. This collaboration aims not only to validate the synergistic effects of the two innovative drugs but also to break through the efficacy ceiling of existing immunotherapy by using the "three-axis" strategy of "immunity + anti-angiogenesis + adenosine inhibition relief", striving for a significant extension of overall survival (OS) for cancer patients.